Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

NUMC Adds Patient Monitoring Capabilities With Masimo Pulse Oximetry & CO-Oximetry Conversion

Nassau University Medical Center (NUMC) and Masimo, the inventor of Pulse CO-Oximetry and Measure-Through Motion and Low Perfusion pulse oximetry, have completed NUMC's system-wide conversion to Masimo oximetry technologies.

The system-wide conversion ensures that NUMC patients will be monitored noninvasively using the most technologically and clinically-advanced pulse oximetry and Pulse CO-Oximetry technologies available providing real-time results for vital measurements that help clinicians to more rapidly assess, diagnose, and treat patients.

The conversion standardizes all of NUMC’s sites of care to Masimo technology, which involved upgrading the hospital’s multiparameter patient monitors, pulse oximeters, and sensors. Masimo offers the upgradeable pulse oximetry technology platform, Masimo Rainbow SET Pulse CO-Oximetry, that allows hospitals to add breakthrough noninvasive blood constituent measurement capabilities that previously required invasive procedures.

The ability to continuously and noninvasively measure many respiratory events enables monitoring of multiple physiological parameters simultaneously to help clinicians detect life-threatening conditions and help guide treatment options.

Joesaid Kiani, founder and CEO of Masimo, said: “Nassau University Medical Center’s conversion to Masimo’s oximetry technology provides clinicians with the patient monitoring tools they need to increase early detection of physiological deterioration and improve safety.

“The noninvasive and continuous measurements provided by Masimo Rainbow SET Pulse CO-Oximetry arms clinicians with new visibility into the physiology and underlying condition of their patients helping to expand their clinical capabilities.”

Paul Weinberg, chairman of Anesthesia at Nassau University Medical Center, said: “Converting to Masimo has greatly advanced our noninvasive patient monitoring capabilities and we’ve been particularly happy with the time it saves us during critical trauma cases.

“With Masimo noninvasive hemoglobin, we see the trend much quicker so we know where the patient’s blood volume is heading and can better anticipate what needs to be done. It’s unique to have immediate access to this level of clinical detail with the ability to track blood levels so accurately.”